AzTrials
AzTrials

Moderate Acute MalnutritionNCT06045104

Alternative Feeding Regimen on Recovery of Children Aged 6-59 Months With Moderate Acute Malnutrition in Bangladesh.

A study testing Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling and 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling in people with Moderate Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In spite of the large burden of acute malnutrition in the country, the Community-based Management of Acute Malnutrition (CMAM) protocol approved in Bangladesh highly deviates from the WHO normative guidance, in that it does not support the use of any currently existing nutritional products for Moderate Acute… Read more about this study

Who is it for?
Ages 6 to 59 months
Conditions the study is for
Moderate Acute Malnutrition
What is being tested?
Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling and 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
Could I receive a placebo?
No, everyone receives an active treatment
How many people
560 participants
Where
1 siteBangladesh
Study dates
20 Oct 2023to 30 Apr 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 59 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children of either sex, aged between 6-59 months having MUAC <125 mm and/or WHZ/WLZ <-2 SD
  • Absence of edema or morbidities that necessitate hospitalization
  • Children with appetite
  • Mothers/caregivers sign the consent form
  • Willing to bring the child to the study site every two weeks for MAM and have a plan to stay in the community for at least next 9-10 months.
  • Accept the intervention package and home visits for data collection and morbidity follow up

Who cannot join

  • Bipedal edema
  • MAM with clinically severe anemia, suspected tuberculosis, other chronic diseases or any congenital disorder or deformity, an ongoing episode of diarrhea, a history of persistent diarrhea in the past month.

Trial locations and contacts

1 site in 1 country.

M Munirul Islam, PhD contact

+8801713006878

mislam@icddrb.org

Md Munirul Islam, PhD contact

+8801713006878

mislam@icddrb.org

Bangladesh1 site
  • Community Clinics

    Teknāf, 4760

    Md Munirul Islam, PhD, +8801713006878, mislam@icddrb.org

    Tahmeed Ahmed, PhD

Other trials in Bangladesh

About this study

Official title: Effectiveness of Context-adapted Alternative Feeding Regimen on Recovery of Children Aged 6-59 Months From Moderate Acute Malnutrition and Uncomplicated Severe Acute Malnutrition in Bangladesh. A Cluster Randomized Control Trial

In spite of the large burden of acute malnutrition in the country, the Community-based Management of Acute Malnutrition (CMAM) protocol approved in Bangladesh highly deviates from the WHO normative guidance, in that it does not support the use of any currently existing nutritional products for Moderate Acute Malnutrition (MAM) cases: it relies solely on nutrition counselling. On another hand, some non-governmental organizations (NGOs) are implementing programs making a standard use of specialized nutritional products, such as nutritional supplements like Wheat Soy Blend (WSB)++ to manage MAM cases, in children of Forcibly Displaced Myanmar Nationals (FDMNs) in the refugee camps situated at the south-eastern region of the country and in some crisis-affected districts as well.

The "no-food" CMAM policy for MAM is decreasing the cost of treatment, yet this may undermine effectiveness and impact. In this context, policy makers need evidence regarding context specific, effective and scalable interventions for CMAM.

Read more

This cluster randomized control trial (cRCT) will be conducted in the host communities in Teknaf and Ukhiya sub-districts of Cox's Bazar district of Bangladesh among children aged 6-59 months suffering from MAM who will be assigned to receive either of the 2 different treatment packages for a period of 4 months (120 days). Then followed up for 6 months (180 days) post treatment completion. Each arm will consist of 280 children with MAM. Both the arms will receive nutrition counselling along with the study intervention, as follows:

In the first arm, the treatment packages for children with MAM will include a standard use of specialized nutritional products developed to address the nutritional needs of these children in acute crisis/emergency settings and widely used internationally: children with MAM will receive WSB++ with nutrition counselling for a period of 4 months (120 days),.

In the second arm, children with MAM will receive 15 MNP with improved nutrition counselling for a period of 4 months (120 days).

A cluster sampling technique will be used to enroll participants. Each Community Clinic and Union Health \& Family Welfare Centers will serve as unit of cluster for the randomization.

Primary outcome variables are: 1) Daily weight gain (g/kg/d) between enrolment and end of the treatment period. 2) Recovery rate (%) at the end of the treatment period.

Read the detailed description

Background

Burden:

Acute Malnutrition (AM) which is also known as 'wasting' in children under five years of age is a major and significant global health problem. It has two forms: i) Severe Acute Malnutrition [(SAM, defined as weight-for-height/length z-score (WHZ/WLZ) less than -3 standard deviations (SDs) from the median of reference population and or Mid-Upper Arm Circumference (MUAC) < 115mm, and or presence of bipedal edema)], and ii) Moderate Acute Malnutrition [(MAM, defined as WHZ/WLZ between -3SDs and <-2SDs and or MUAC ≥ 115mm to <125mm)]. It is estimated that more than half of all under five deaths are associated with undernutrition. Both MAM and SAM pose serious consequences, leading to increased morbidity and mortality, impaired intellectual development, increased risk of non-communicable diseases (NCDs) in adulthood, and suboptimal adult work capacity. Children with SAM have approximately nine times and children with MAM have approximately three times higher risk of mortality due to common communicable diseases than if they were well-nourished. A MAM child is additionally at higher risk of developing SAM if their health and nutritional condition is not monitored. The recent Lancet analysis estimated that in 2020, the COVID19 pandemic exacerbated the problem of AM with an additional 6.7 million children - equivalent to a 14.3% increase in the number of children with wasting. More than half (3.9 million) of these children would be from South Asia alone. Although prevalence of AM in many countries have reduced, still these are far from Sustainable Development Goals (SDGs) target.

Despite Bangladesh already progressed in reduction of AM by more than half between 2007 and 2017, still it has one of the highest prevalence of AM in the world. According to Bangladesh Demographic and Health Survey (BDHS) 2017 prevalence of AM under-5 children was 8.4%, while the multiple indicator cluster survey (MICS) which included a larger sample, found a slight increase from 9.6% in 2013 to 9.8% (1.5 million) in 2019. Of the total AM, 7.5% (1.1-1.2 million) were MAM. It depicts that currently in terms of reducing the prevalence of wasting among children under five to <5 %, Bangladesh has to go far away to achieve the SDG target 2.2 by 2025. It was observed that despite having recovery rate above the minimum standards of >75%, post-discharge relapse rates of AM were very high (78% for MAM 69% while 9% for SAM) in Bangladesh and Southern Ethiopia 72.1% (37.5% for MAM and 34.6% for SAM). Chang et al. 2013 found 27% (17% for MAM and 10% for SAM) relapse cases in Malawi. Therefore, after recovery and discharge a child should be followed up to assess the maintenance of the nutritional status, because it is likely that children who recovered from AM may recur as AM after returning to the same environment.

Knowledge gap:

Based on the current consensus, children with MAM should also be managed at home/community. Essential nutrition activities such as breastfeeding promotion and support, education and nutrition counselling for caregivers should be an integral part of management of children aged 6-59 months with MAM or uncomplicated SAM. WHO 19 Technical Group and Community Management of Acute Malnutrition (CMAM) Forum, 2014 recommended nutritional supplements and nutrition counselling for children with MAM. However, the latest WHO recommendation on MAM management is that it should not provide nutritional supplements routinely unless the context is highly food insecure (WHO 2017).

In Bangladesh, children with MAM receive basic medical treatment, and mothers/caregivers are provided with counselling on the use of high energy/nutrient dense local foods fortified with micronutrients in the outpatient care. Community outreach activities are given priority in promotion and support of appropriate infant and young child feeding (IYCF) practices, identification, care, referral, and follow up of children with AM.

Relevance:

In spite of the large burden of acute malnutrition in the country, the CMAM protocol approved in Bangladesh highly deviates from the WHO normative guidance, in that it does not support the use of any currently existing nutritional products for MAM cases: it relies solely on nutrition counselling. On another hand, some non-governmental organizations (NGOs) are implementing programs making a standard use of specialized nutritional supplements like Wheat Soy Blend (WSB)++ to manage MAM cases, in children of Forcibly Displaced Myanmar Nationals (FDMNs) in the refugee camps situated at the south-eastern region of the country and in some crisis-affected districts as well.

The "no-food" CMAM policy for MAM is decreasing the cost of treatment, yet this may undermine effectiveness and impact. In this context, policy makers need evidence regarding context specific, effective and scalable interventions for CMAM.

Hypothesis:

The study hypothesizes that improved nutrition counselling provided together with 15 MNP is equally effective (recovery rate) as super cereal (WSB++) in treating children aged 6-59 months with MAM for a period of 4 months (120 days).

Objectives:

Primary Objectives

  1. To assess the daily weight gain and recovery rate among MAM children aged 6-59 months provided with 15 MNP with improved nutrition counselling and WSB++ with nutrition counselling provided for a period of 4 months (120 days).
  2. To identify the predictors for the 'not recovered/non-responder' to the treatment(s) and regression to SAM among MAM children at the end of 4 months (120 days).

Secondary objectives

  1. To evaluate the effects of nutrition counselling combined with 15 MNP and WSB++ on relapse of MAM children during a period of 6 months (180 days) post treatment (long term).
  2. To evaluate the effects of nutrition counselling combined with 15 MNP and WSB++ provided solely on body composition (lean and fat mass) of MAM children at the end of 4 months (120 days) and 6 months (180 days) post treatment (long term).
  3. To evaluate the effects of nutrition counselling combined with 15 MNP and WSB++ on cognitive development of MAM children at the end of 4 months (120 days) and 6 months (180 days) post treatment (long term).
  4. To identify concurrent illness, and gut microbiota (in a sub-sample) at baseline and end of intervention period.
  5. To evaluate the cost-effectiveness of community management of MAM children aged 6-59 months provided with nutrition counselling combined with 15 MNP and WSB++.
  6. To define challenges and opportunities in scaling up the tested intervention(s) if proven to be effective alone or cost effective as well.

Methods:

Study site:

The study will be conducted in the host communities in Teknaf and Ukhiya sub-districts of Cox's Bazar district of Bangladesh.

Study Population:

This trial will be conducted in children aged 6-59 months with MAM residing in Teknaf and Ukhiya sub-districts of Cox's Bazar district of Bangladesh.

Inclusion criteria

The inclusion criteria for enrolment in the study will include:

  1. Children of either sex, aged between 6-59 months having MUAC <125 mm and/or WHZ/WLZ <-2 SD ii) Absence of edema or morbidities that necessitate hospitalization iii) Children with appetite iv) Mothers/caregivers sign the consent form v) Willing to bring the child to the study site every two weeks for MAM and have a plan to stay in the community for at least next 9-10 months. vi) Accept the intervention package and home visits for data collection and morbidity follow up.

Exclusion criteria:

The study will not include children with- i) Bipedal edema ii) MAM with clinically severe anemia, suspected tuberculosis, other chronic diseases or any congenital disorder or deformity, an ongoing episode of diarrhea, a history of persistent diarrhea in the past month.

iii) Complicated SAM cases

Study plan In this cluster randomized-controlled trial (cRCT), 560 eligible MAM children will be enrolled, treated for 4 months (120 days) and then followed up for 6 months (180 days) post treatment completion.

Study design

This cluster randomized control trial (cRCT) will include children aged 6-59 months suffering from MAM who will be assigned to receive either of the 2 different treatment packages for a period of 4 months (120 days). Then followed up for 6 months (180 days) post treatment completion. Each arm will consist of 280 children with MAM. Both the arms will receive nutrition counselling along with the study intervention, as follows:

In the first arm, the treatment packages for children with MAM will include a standard use of specialized nutritional products developed to address the nutritional needs of these children in acute crisis/emergency settings and widely used internationally: children with MAM will receive WSB++ with nutrition counselling for a period of 4 months (120 days).

In the second arm, children with MAM will receive 15 MNP with improved nutrition counselling for a period of 4 months (120 days).

Sampling technique A cluster sampling technique will be used to enroll participants. Each Community Clinic and Union Health \& Family Welfare Centers will serve as unit of cluster for the randomization.

Field implementation of the interventions:

The intervention will take place in 28 community clinics (CCs) and 6 Union Health \& Family Welfare Centers (UH\&FWCs) in the host communities in Teknaf and Ukhiya sub-districts of Cox's Bazar district of Bangladesh. As per the national CMAM guidelines, all the participating CC/UH\&FWC provides the standard care and nutrition counselling for children with MAM or uncomplicated SAM. Children with MAM from catchment areas of the selected 10 CCs/ UH\&FWCs will take part in each arm. Research team, Community Health Care Providers (CHCPs), Health Assistants (HAs), Family Welfare Assistants (FWAs) and local NGO's field workers will work to conduct this study. All participating children would be receiving standard health and nutrition counselling at each occasion they attend the CCs/UH\&FWC

Outcome measures/variables:

Primary effectiveness outcomes

  1. Daily weight gain (g/kg/d) between enrolment and end of the treatment period (for 4 months or 120 days). If recovery was reached before the full duration of the treatment, daily weight gain will be calculated between enrolment and recovery, without stopping the treatment.
  2. Recovery rate (%) at the end of the treatment period (4 months or 120 days)
  3. Proportion of children free from acute malnutrition at the end of the treatment period (4 months or 120 days)

Secondary effectiveness outcomes

  1. Proportion of non-response, death, defaulter and regression of MAM to SAM (among MAM children) at the end of treatment period (4 months or 120 days).
  2. Incidence of relapse during a period of 6 months (180 days) post-treatment
  3. Change in lean and fat mass between enrollment and end of the treatment period (4 months or 120 days) and 6 months post-treatment
  4. Prevalence of concurrent infections at the end of the treatment period (4 months or 120 days) and 6 months post-treatment
  5. Motor, language, and personal-social development at the end of the treatment period (4 months or 120 days) and 6 months post-treatment
  6. Cost-effectiveness analysis
  7. Challenges and opportunities in scaling up the tested intervention(s)
  8. Feasibility and acceptability of the interventions
  9. Knowledge, attitudes and practices regarding nutritional and social care of MAM

Safety outcomes

  • Incidence of diarrhea, pneumonia, malaria etc. among children during study period (9-10 months)
Being tested
Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling, 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
Keywords
Moderate Acute Malnutrition, Children, Wheat Soy Blend ++, 15 MNP

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Wheat Soy Blend Plus Plus (WSB++) with nutrition counsellingDietary supplement

    Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling

  • 15 Micro Nutrient Powder (15 MNP) with improved nutrition counsellingDietary supplement

    15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling

Study groups in NCT06045104
Study groupRoleWhat they receive
Wheat Soy Blend Plus Plus (WSB++) with nutrition counsellingActive comparatorWheat Soy Blend Plus Plus (WSB++) with nutrition counselling
Receives: Dietary Supplement: Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
15 Micro Nutrient Powder (15 MNP) with improved nutrition counsellingExperimental15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
Receives: Dietary Supplement: 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of weight gain (g/kg/d)

    Daily weight gain (g/kg/d) between enrolment and end of the treatment period. If recovery was reached before the full duration of the treatment, daily weight gain will be calculated between enrolment and recovery, without stopping the treatment.

    Measured: 4 months or 120 days

  2. Recovery rate (%)

    Recovery rate (%) at the end of the treatment period

    Measured: 4 months or 120 days

  3. Free from acute malnutrition

    Proportion of children free from acute malnutrition at the end of the treatment period

    Measured: 4 months or 120 days

Secondary outcomes (5)
  1. Proportion of non-response, death, defaulter and regression of MAM to SAM

    Proportion of non-response, death, defaulter and regression of MAM to SAM (among MAM children) at the end of treatment period

    Measured: 4 months or 120 days

  2. Incidence of relapse during a period of 6 months (180 days) post-treatment

    Incidence of relapse during a period of 6 months (180 days) post-treatment

    Measured: 6 months or 180 days post treatment

  3. Change in lean and fat mass between enrollment and end of the treatment period

    Change in lean and fat mass between enrollment and end of the treatment period

    Measured: 4 months or 120 days) and 6 months post-treatment

  4. Prevalence of concurrent infections at the end of the treatment period

    Prevalence of concurrent infections at the end of the treatment period

    Measured: 4 months or 120 days) and 6 months post-treatment

  5. Motor, language, and personal-social development at the end of the treatment period

    Motor, language, and personal-social development at the end of the treatment period

    Measured: 4 months or 120 days) and 6 months post-treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2023
  2. Study start20 Oct 2023 (estimated)
  3. Primary completion30 Apr 2025 (estimated)
  4. Study completion30 Apr 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
560 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06045104
Sponsor's protocol ID
PR-22128-A
Status last verified
Sep 2023
First submitted
13 Sep 2023
Last updated
13 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling and 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling in people with Moderate Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact M Munirul Islam, PhD (+8801713006878, mislam@icddrb.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of weight gain (g/kg/d) (time frame: 4 months or 120 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in